Gamma Heavy Chain Disease Follow-up

1. Mrosewski I, Urbank M. Gamma Heavy Chain Disease - Diagnostic Challenges in an Unusual Case and a Brief Synopsis of the Current Literature. Clin Lab. 2020 Jan 1. 66 (1):[Medline].

2. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. 154.

3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19. 127 (20):2375-90. [Medline]. [Full Text].

4. Hamadeh F, MacNamara S, Bacon CM, Sohani AR, Swerdlow SH, Cook JR. Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma. Haematologica. 2014 Sep. 99 (9):e154-5. [Medline]. [Full Text].

5. Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. Gamma-heavy chain disease: review of 23 cases. Medicine (Baltimore). 2003 Jul. 82(4):236-50. [Medline].

6. Husby G, Blichfeldt P, Brinch L, et al. Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link?. Scand J Rheumatol. 1998. 27(4):257-64. [Medline].

7. Husby G. Is there a pathogenic link between gamma heavy chain disease and chronic arthritis?. Curr Opin Rheumatol. 2000 Jan. 12(1):65-70. [Medline].

8. Faguet GB, Barton BP, Smith LL, Garver FA. Gamma heavy chain disease: clinical aspects and characterization of a deleted, noncovalently linked gamma1 heavy chain dimer (BAZ). Blood. 1977 Apr. 49(4):495-505. [Medline].

9. Seligmann M, Mihaesco E, Preud'homme JL, Danon F, Brouet JC. Heavy chain diseases: current findings and concepts. Immunol Rev. 1979. 48:145-67. [Medline].

10. Bianchi G, Anderson KC, Harris NL, Sohani AR. The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014 Jan. 28 (1):45-53. [Medline].

11. Wester SM, Banks PM, Li CY. The histopathology of gamma heavy-chain disease. Am J Clin Pathol. 1982 Oct. 78(4):427-36. [Medline].

12. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, et al. Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution. Clin J Am Soc Nephrol. 2011 Dec 8. [Medline].

13. Tissot JD, Tridon A, Ruivard M, et al. Electrophoretic analyses in a case of monoclonal gamma chain disease. Electrophoresis. 1998 Jul. 19(10):1771-3. [Medline].

14. Csako G. Immunodeletrophoresis: A method with many facets. Biji T, Kurien R, Schofield H. Protein Electrophoresis and Protocols, Methods in Molecular Biology. Springer Sciences-Business Media, LLC; 2012. 869:

15. Gale DS, Versey JM, Hobbs JR. Rocket immunoselection for detection of heavy-chain diseases. Clin Chem. 1974 Oct. 20(10):1292-4. [Medline].

16. Takano H, Nagata K, Mikoshiba M, Nakane M, Kato A, Hamaguchi H. Combination of rituximab and chemotherapy showing anti-tumor effect in gamma heavy chain disease expressing CD20. Am J Hematol. 2008 Dec. 83(12):938-9. [Medline].

17. Inoue D, Matsushita A, Kiuchi M, et al. Successful treatment of ?-heavy-chain disease with rituximab and fludarabine. Acta Haematol. 2012. 128(3):139-43. [Medline].

18. Agrawal S, Abboudi Z, Matutes E, Catovsky D. First report of fludarabine in gamma-heavy chain disease. Br J Haematol. 1994 Nov. 88(3):653-5. [Medline].

19. Yeh CH, Tseng R, Albitar M. Plasma-based detection of clonality in lymphoid malignancies. Eur J Haematol. 2009 Jun. 82(6):450-3. [Medline].

20. Zhang Y, Chen L, Xu W, et al. [Immunoglobulin variable heavy chain region genetic constitution and mutation status in Chinese patients with chronic lymphocytic leukemia] [Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009 Apr. 26(2):196-9. [Medline].

Guy B Faguet, MD Retired Professor, Department of Medicine, Section of Hematology and Oncology, Georgia Regents University

Guy B Faguet, MD is a member of the following medical societies: American Association of Immunologists, American Society of Hematology, International Society of Hematology, New York Academy of Sciences, Southern Medical Association, Southern Society for Clinical Investigation, American Federation for Clinical Research, Southeastern Cancer Research Association, Polycythemia Vera Study Group

Disclosure: Nothing to disclose.

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Wendy Brick, MD Consulting Staff, Department of Internal Medicine, Division of Hematology and Oncology, Mecklenburg Medical Group

Wendy Brick, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, and American Society of Hematology

Disclosure: Nothing to disclose.

Russell Burgess, MD (Retired) Chief, Division of Hematology/Oncology, Eastern Carolina Internal Medicine, PA

Russell Burgess, MD is a member of the following medical societies: American College of Physicians and American Medical Assocation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article